Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Megyn Kelly Slams Oprah's 'Obesity Gene' as GLP-1 Cop-Out - Featured image
Weight Management

Megyn Kelly Slams Oprah's 'Obesity Gene' as GLP-1 Cop-Out

Shotlee Editorial Team
Written by Shotlee Editorial TeamHealth Research & Writing
·January 17, 2026·2 min read

On this page

  • Oprah Winfrey's Take on Obesity and GLP-1
  • Megyn Kelly's Response: A 'Cop-Out'?
  • Debate on Personal Responsibility and Side Effects
  • Key Implications for Weight Management

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

Conservative commentator Megyn Kelly labeled Oprah Winfrey's attribution of overeating to an 'obesity gene' a cop-out. In discussions around Winfrey's book with Dr. Ania Jastreboff, GLP-1 medications are highlighted for silencing food noise. Kelly argues millions manage food thoughts without obesity through self-discipline.

Share

On this page

  • Oprah Winfrey's Take on Obesity and GLP-1
  • Megyn Kelly's Response: A 'Cop-Out'?
  • Debate on Personal Responsibility and Side Effects
  • Key Implications for Weight Management

Conservative podcaster Megyn Kelly criticized Oprah Winfrey for remarks linking overeating to an "obesity gene" in a new book on obesity and GLP-1 medications.

Oprah Winfrey's Take on Obesity and GLP-1

Oprah Winfrey collaborated with endocrinologist Dr. Ania Jastreboff on Enough: Your Health, Your Weight and What It's Like to Be Free, released January 13 by Avid Reader Press. Winfrey shared her weight loss journey, crediting GLP-1 drugs for quieting constant "food noise"—an urge to eat.

On The View, Winfrey stated: "I understand that if you carry the obesity gene, if that is what you have, that is what makes you overeat. You don't overeat and become obese. Obesity causes you to overeat." She described food noise as a lifelong challenge for those with obesity.

Megyn Kelly's Response: A 'Cop-Out'?

In her January 16 podcast episode, Kelly discussed Winfrey's comments with journalist Maureen Callahan. Kelly said: "I do like I have nothing against the GLP-1s, but I do think this like, 'It's a disease and I had no personal responsibility in my morbidly obese body' is a cop-out."

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

Kelly countered that food thoughts are human: "It's called being human... We all love it. You eat out of boredom. I mean, millions of Americans who have never been obese have that food conversation in their head, but they managed to say no."

Debate on Personal Responsibility and Side Effects

Callahan noted Winfrey's past claims of her weight struggles being uniquely exploited. She called it Winfrey's "favorite narrative." Both raised questions about GLP-1 drugs, with Callahan citing reports of severe side effects from users.

  • Callahan reviewed the book: Winfrey contributed a short foreword, while Dr. Jastreboff wrote most of it.
  • Kelly viewed the book as another publicity move.

Winfrey promoted the book and her shifted obesity views, including a January 13 podcast with Serena Williams discussing GLP-1 medications.

Key Implications for Weight Management

The exchange highlights tensions between genetic factors, GLP-1 therapies, and discipline in weight management. While Winfrey emphasizes biology and drug benefits, critics stress behavioral control.

Source Information

Originally published by Sportskeeda.Read the original article →

Read next

Keep exploring

Same topic: GLP-1 Medications

All GLP-1 Medications articles →
What's the Deal with Peptides? The Hyped Market Under FDA Review
Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read
Truth About Mounjaro Jowls: Rosie O'Donnell's Facelift That Can't Hide Weight Loss
Medication & Weight Management

Truth About Mounjaro Jowls: Rosie O'Donnell's Facelift That Can't Hide Weight Loss

Rapid weight loss on GLP-1 medications often leads to skin laxity because the body loses subcutaneous fat faster than collagen and elastin can regenerate. This biological lag creates visible sagging, particularly in areas with high elasticity like the jawline and neck.

6 min read

More in Weight Management

Retatrutide: A New Era in Weight Loss Drugs vs. Ozempic
Weight Management

Retatrutide: A New Era in Weight Loss Drugs vs. Ozempic

Eli Lilly's experimental drug retatrutide has demonstrated unprecedented weight loss results in a pivotal trial. This article delves into its mechanisms, efficacy, safety, and how it stacks up against current leading weight loss medications like Ozempic and Wegovy.

6 min read
New Procedure May Combat Weight Regain After GLP-1s
Weight Management

New Procedure May Combat Weight Regain After GLP-1s

Losing weight with GLP-1 medications like semaglutide and tirzepatide is a significant achievement, but maintaining that loss after stopping treatment presents a major challenge. A new experimental procedure, duodenal mucosal resurfacing (DMR), is showing remarkable potential in helping individuals keep the pounds off.

7 min read
Ozempic Book Reframes Obesity Views in GLP-1 Era
GLP-1 Medications

Ozempic Book Reframes Obesity Views in GLP-1 Era

A new book, 'Off the Scales,' reveals how Ozempic and GLP-1 drugs are reshaping societal views on obesity. Author Aimee Donnellan details their development, profound weight loss effects, and the urgent need for medical approaches to this growing crisis. Learn why these therapies mark a turning point in weight management.

2 min read
Share this article
  1. Home
  2. Blog
  3. Megyn Kelly Slams Oprah's 'Obesity Gene' as GLP-1 Cop-Out
Shotlee Editorial Team — Health Research & Writing
Written by

Shotlee Editorial Team

Health Research & Writing

Shotlee’s guides and articles are researched and written in-house by the Shotlee Editorial Team. We build every page from primary sources — FDA labels, official prescribing information, and peer-reviewed clinical trials — and cite them directly. Our content is educational and is not a substitute for advice from your own healthcare provider.

View all articles by Shotlee Editorial Team
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community